3 High Potential SEHK Growth Companies With At Least 19% Insider Ownership

The Hong Kong market has shown resilience with the Hang Seng Index gaining 3.11% amid global economic fluctuations and specific local interventions aimed at stabilizing key sectors. In such a market environment, growth companies with high insider ownership in Hong Kong may offer unique advantages, as substantial insider stakes often align shareholder interests with robust corporate governance and long-term strategic commitments.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name	Insider Ownership	Earnings Growth
iDreamSky Technology Holdings (SEHK:1119)	20.1%	104.1%
New Horizon Health (SEHK:6606)	16.6%	61%
Meitu (SEHK:1357)	38%	34.3%
Adicon Holdings (SEHK:9860)	22.3%	29.6%
DPC Dash (SEHK:1405)	38.2%	91.5%
Tian Tu Capital (SEHK:1973)	34%	70.5%
Zhejiang Leapmotor Technology (SEHK:9863)	14.2%	75.4%
Beijing Airdoc Technology (SEHK:2251)	27.2%	83.9%
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)	15.7%	100.1%
Ocumension Therapeutics (SEHK:1477)	17.7%	93.7%

Click here to see the full list of 52 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

Kuaishou Technology (SEHK:1024)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Kuaishou Technology operates as an investment holding company in the People's Republic of China, offering services such as live streaming and online marketing, with a market capitalization of approximately HK$256.42 billion.

Operations: The company generates revenue primarily through live streaming and online marketing services.

Insider Ownership: 19.3%

Kuaishou Technology, a growth-oriented firm in Hong Kong, has recently transitioned to profitability and is demonstrating robust earnings growth, expected at 23.56% annually. Despite revenue growth projections being modest compared to some market benchmarks (10% per year), the company's strategic maneuvers, including a substantial share repurchase program valued at HK$16 billion valid until 2027, signal strong confidence from management. This aligns with its high insider ownership ethos but lacks recent insider trading activity to further bolster investor confidence in its governance and future prospects.

• Navigate through the intricacies of Kuaishou Technology with our comprehensive analyst estimates report here.
• The valuation report we've compiled suggests that Kuaishou Technology's current price could be quite moderate.

Tian Tu Capital (SEHK:1973)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Tian Tu Capital Co., Ltd. is a private equity and venture capital firm focusing on investments in small and medium-sized companies at various stages, including early-stage, mature, and Pre-IPO, with a market capitalization of approximately HK$2.79 billion.

Operations: The company's revenue from asset management is CN¥-0.77 billion.

Insider Ownership: 34%

Tian Tu Capital, a Hong Kong-based company, is navigating a challenging phase with significant management changes and no dividend payment recommended for 2023. Despite these hurdles, the company's revenue growth is projected to significantly outpace the market at 63.2% annually. Although currently operating at a loss with an expected net loss up to RMB 890 million for the year ended December 31, 2023, Tian Tu Capital is forecasted to reach profitability within three years and trades at a substantial discount to its estimated fair value.

• Click here and access our complete growth analysis report to understand the dynamics of Tian Tu Capital.
• According our valuation report, there's an indication that Tian Tu Capital's share price might be on the cheaper side.

CanSino Biologics (SEHK:6185)

Simply Wall St Growth Rating: ★★★★★☆

Overview: CanSino Biologics Inc. is a company based in the People's Republic of China that focuses on developing, manufacturing, and commercializing vaccines, with a market capitalization of approximately HK$9.66 billion.

Operations: The company generates revenue primarily through its research and development of vaccine products for human use, totaling CN¥370.81 million.

Insider Ownership: 27.9%

CanSino Biologics, a growth-focused biotech firm in Hong Kong, is expected to achieve profitability within three years amid robust revenue growth projections of 34.3% annually, outpacing the local market's 8% growth rate. Despite its recent net loss of CNY 170.1 million in Q1 2024, the company is trading at a significant discount to its fair value and continues to innovate with new vaccine trials, including approvals for clinical trials for Hib and PBPV vaccines. However, its forecasted Return on Equity remains low at 5.1%.

• Delve into the full analysis future growth report here for a deeper understanding of CanSino Biologics.
• Our expertly prepared valuation report CanSino Biologics implies its share price may be too high.

Make It Happen

• Unlock our comprehensive list of 52 Fast Growing SEHK Companies With High Insider Ownership by clicking here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com